# Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer

> **NCT02873416** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ningbo Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Precision Cell Immunotherapy
- Chemotherapy
- Advanced Lung Cancer

## Interventions

- **DRUG:** Chemotherapy
- **BIOLOGICAL:** Precision Cells

## Key facts

- **NCT ID:** NCT02873416
- **Lead sponsor:** Ningbo Cancer Hospital
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2018-03
- **Final completion:** 2018-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873416, "Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02873416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*